Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VICENTE VALERO and HENRY MARK KUERER.
VICENTE VALERO
Connection Strength
2.723
HENRY MARK KUERER
  1. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 12; 268(6):e61-e62.
    View in: PubMed
    Score: 0.661
  2. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol. 2024 Aug 22; 50(12):108613.
    View in: PubMed
    Score: 0.246
  3. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
    View in: PubMed
    Score: 0.222
  4. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524.
    View in: PubMed
    Score: 0.216
  5. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
    View in: PubMed
    Score: 0.173
  6. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.159
  7. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.150
  8. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
    View in: PubMed
    Score: 0.137
  9. Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg. 2016 Feb; 137(2):385-393.
    View in: PubMed
    Score: 0.136
  10. ASO Visual Abstract: Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2024 Oct 23.
    View in: PubMed
    Score: 0.062
  11. Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2024 Oct 17.
    View in: PubMed
    Score: 0.062
  12. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol. 2024 Oct; 31(11):7264-7270.
    View in: PubMed
    Score: 0.061
  13. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):443-454.
    View in: PubMed
    Score: 0.058
  14. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933.
    View in: PubMed
    Score: 0.057
  15. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8.
    View in: PubMed
    Score: 0.051
  16. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
    View in: PubMed
    Score: 0.049
  17. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
    View in: PubMed
    Score: 0.048
  18. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast?Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25.
    View in: PubMed
    Score: 0.034
  19. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.033
  20. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.030
  21. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6.
    View in: PubMed
    Score: 0.026
  22. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93.
    View in: PubMed
    Score: 0.025
  23. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.016
  24. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.